Literature DB >> 33549119

The crosstalk of HDAC3, microRNA-18a and ADRB3 in the progression of heart failure.

Jingtao Na1, Haifeng Jin2, Xin Wang3, Kan Huang3, Shuang Sun3, Qiang Li3, Wenting Zhang4.   

Abstract

BACKGROUND: Heart failure (HF) is a clinical syndrome characterized by left ventricular dysfunction or elevated intracardiac pressures. Research supports that microRNAs (miRs) participate in HF by regulating  targeted genes. Hence, the current study set out to study the role of HDAC3-medaited miR-18a in HF by targeting ADRB3.
METHODS: Firstly, HF mouse models were established by ligation of the left coronary artery at the lower edge of the left atrial appendage, and HF cell models were generated in the cardiomyocytes, followed by ectopic expression and silencing experiments. Numerous parameters including left ventricular posterior wall dimension (LVPWD), interventricular septal dimension (IVSD), left ventricular end diastolic diameter (LVEDD), left ventricular end systolic diameter (LVESD), left ventricular ejection fraction (LVEF), left ventricular fractional shortening (LVFS), left ventricular systolic pressure (LVSP), left ventricular end diastolic pressure (LEVDP), heart rate (HR), left ventricular pressure rise rate (+ dp/dt) and left ventricular pressure drop rate (-dp/dt) were measured in the mice. In addition, apoptosis in the mice was detected by means of TUNEL staining, while RT-qPCR and Western blot analysis were performed to detect miR-18a, HDAC3, ADRB3, cMyb, MMP-9, Collagen 1 and TGF-β1 expression patterns. Dual luciferase reporter assay validated the targeting relationship between ADRB3 and miR-18a. Cardiomyocyte apoptosis was determined by means of flow cytometry.
RESULTS: HDAC3 and ADRB3 were up-regulated and miR-18a was down-regulated in HF mice and cardiomyocytes. In addition, HDAC3 could reduce the miR-18a expression, and ADRB3 was negatively-targeted by miR-18a. After down-regulation of HDAC3 or ADRB3 or over-expression of miR-18a, IVSD, LVEDD, LVESD and LEVDP were found to be decreased but LVPWD, LVEF, LVFS, LVSP, + dp/dt, and -dp/dt were all increased in the HF mice, whereas fibrosis, hypertrophy and apoptosis of HF cardiomyocytes were declined.
CONCLUSION: Collectively, our findings indicate that HDAC3 silencing confers protection against HF by inhibiting miR-18a-targeted ADRB3.

Entities:  

Keywords:  ADRB3; Fibrosis; HDAC3; Heart failure; Hypertrophy; microRNA-18a

Year:  2021        PMID: 33549119     DOI: 10.1186/s13578-020-00523-y

Source DB:  PubMed          Journal:  Cell Biosci        ISSN: 2045-3701            Impact factor:   7.133


  45 in total

Review 1.  MicroRNAs in heart failure: from biomarker to target for therapy.

Authors:  Eline L Vegter; Peter van der Meer; Leon J de Windt; Yigal M Pinto; Adriaan A Voors
Journal:  Eur J Heart Fail       Date:  2016-02-11       Impact factor: 15.534

2.  Transcoronary concentration gradients of circulating microRNAs in heart failure.

Authors:  Salvatore De Rosa; Francesca Eposito; Cristina Carella; Antonio Strangio; Giuseppe Ammirati; Jolanda Sabatino; Fabio Giovanni Abbate; Claudio Iaconetti; Vincenzo Liguori; Valerio Pergola; Alberto Polimeni; Silvio Coletta; Clarice Gareri; Bruno Trimarco; Giuseppe Stabile; Antonio Curcio; Ciro Indolfi; Antonio Rapacciuolo
Journal:  Eur J Heart Fail       Date:  2018-01-04       Impact factor: 15.534

Review 3.  Heart failure with reduced ejection fraction.

Authors:  Michelle W Bloom; Barry Greenberg; Tiny Jaarsma; James L Januzzi; Carolyn S P Lam; Aldo P Maggioni; Jean-Noël Trochu; Javed Butler
Journal:  Nat Rev Dis Primers       Date:  2017-08-24       Impact factor: 52.329

4.  Prevalence of lactic acidaemia in patients with advanced heart failure and depressed cardiac output.

Authors:  Luigi Adamo; Michael E Nassif; Erik Novak; Shane J LaRue; Douglas L Mann
Journal:  Eur J Heart Fail       Date:  2016-09-20       Impact factor: 15.534

Review 5.  Glucose Metabolism Abnormalities in Heart Failure Patients: Insights and Prognostic Relevance.

Authors:  Fabio Marsico; Paola Gargiulo; Alberto M Marra; Antonio Parente; Stefania Paolillo
Journal:  Heart Fail Clin       Date:  2019-04-05       Impact factor: 3.179

6.  Use of biomarkers to establish potential role and function of circulating microRNAs in acute heart failure.

Authors:  Eline L Vegter; Daniela Schmitter; Yanick Hagemeijer; Ekaterina S Ovchinnikova; Pim van der Harst; John R Teerlink; Christopher M O'Connor; Marco Metra; Beth A Davison; Daniel Bloomfield; Gad Cotter; John G Cleland; Michael M Givertz; Piotr Ponikowski; Dirk J van Veldhuisen; Peter van der Meer; Eugene Berezikov; Adriaan A Voors; Mohsin A F Khan
Journal:  Int J Cardiol       Date:  2016-09-11       Impact factor: 4.164

7.  Effect of a Collaborative Care Intervention vs Usual Care on Health Status of Patients With Chronic Heart Failure: The CASA Randomized Clinical Trial.

Authors:  David B Bekelman; Larry A Allen; Connor F McBryde; Brack Hattler; Diane L Fairclough; Edward P Havranek; Carolyn Turvey; Paula M Meek
Journal:  JAMA Intern Med       Date:  2018-04-01       Impact factor: 21.873

8.  Signature of circulating microRNAs in patients with acute heart failure.

Authors:  Ekaterina S Ovchinnikova; Daniela Schmitter; Eline L Vegter; Jozine M Ter Maaten; Mattia A E Valente; Licette C Y Liu; Pim van der Harst; Yigal M Pinto; Rudolf A de Boer; Sven Meyer; John R Teerlink; Christopher M O'Connor; Marco Metra; Beth A Davison; Daniel M Bloomfield; Gadi Cotter; John G Cleland; Alexandre Mebazaa; Said Laribi; Michael M Givertz; Piotr Ponikowski; Peter van der Meer; Dirk J van Veldhuisen; Adriaan A Voors; Eugene Berezikov
Journal:  Eur J Heart Fail       Date:  2015-09-08       Impact factor: 15.534

9.  Low circulating microRNA levels in heart failure patients are associated with atherosclerotic disease and cardiovascular-related rehospitalizations.

Authors:  Eline L Vegter; Ekaterina S Ovchinnikova; Dirk J van Veldhuisen; Tiny Jaarsma; Eugene Berezikov; Peter van der Meer; Adriaan A Voors
Journal:  Clin Res Cardiol       Date:  2017-03-14       Impact factor: 5.460

Review 10.  Drug treatment effects on outcomes in heart failure with preserved ejection fraction: a systematic review and meta-analysis.

Authors:  Sean Lee Zheng; Fiona T Chan; Adam A Nabeebaccus; Ajay M Shah; Theresa McDonagh; Darlington O Okonko; Salma Ayis
Journal:  Heart       Date:  2017-08-05       Impact factor: 5.994

View more
  4 in total

1.  Expression and Regulation Network of HDAC3 in Acute Myeloid Leukemia and the Implication for Targeted Therapy Based on Multidataset Data Mining.

Authors:  Minhua Li; Feifei Lan; Chen Li; Ning Li; Xiaojie Chen; Yueyuan Zhong; Yue Yang; Yingqi Shao; Yi Kong; Xinming Li; Danny Wu; Jingyu Zhang; Wenqing Chen; Zesong Li; Xiao Zhu
Journal:  Comput Math Methods Med       Date:  2022-03-14       Impact factor: 2.809

Review 2.  The critical roles of histone deacetylase 3 in the pathogenesis of solid organ injury.

Authors:  Li Ning; Xiong Rui; Wang Bo; Geng Qing
Journal:  Cell Death Dis       Date:  2021-07-23       Impact factor: 8.469

3.  MiR-29a Increase in Aging May Function as a Compensatory Mechanism Against Cardiac Fibrosis Through SERPINH1 Downregulation.

Authors:  Evelyn Gabriela Rusu-Nastase; Ana-Mihaela Lupan; Catalina Iolanda Marinescu; Carmen Alexandra Neculachi; Mihai Bogdan Preda; Alexandrina Burlacu
Journal:  Front Cardiovasc Med       Date:  2022-01-18

4.  Identification of novel leads as potent inhibitors of HDAC3 using ligand-based pharmacophore modeling and MD simulation.

Authors:  Navanath Kumbhar; Snehal Nimal; Sagar Barale; Subodh Kamble; Rohit Bavi; Kailas Sonawane; Rajesh Gacche
Journal:  Sci Rep       Date:  2022-02-02       Impact factor: 4.996

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.